Drugs in MeSH Category Angiogenesis Inhibitors

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Natco	THALIDOMIDE	thalidomide	CAPSULE;ORAL	213267-001	Apr 27, 2023		DISCN	No	No
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-004	Jan 10, 2007		RX	Yes	No
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-003	Jan 17, 2003		RX	Yes	Yes

Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Angiogenesis Inhibitors

Last updated: January 20, 2026

---

Summary

This report provides an in-depth analysis of the current market dynamics and patent landscape for angiogenesis inhibitors classified under the Medical Subject Headings (MeSH) term by the National Library of Medicine (NLM). It assesses therapeutic indications, key industry players, patent filing trends, competitive shifts, and regulatory environments, highlighting opportunities and challenges for stakeholders.

---

What Are Angiogenesis Inhibitors?

Angiogenesis inhibitors are drugs designed to block the formation of new blood vessels, a critical process in tumor growth, metastasis, and certain ocular diseases. Their primary mechanism involves targeting vascular endothelial growth factors (VEGF), VEGF receptors, or related signaling pathways.

---

Pharmacological and Therapeutic Overview

Category	Description	Examples	Common Indications
Anti-VEGF antibodies	Monoclonal antibodies targeting VEGF	Bevacizumab (Avastin), Aflibercept	Colorectal cancer, non-small cell lung cancer (NSCLC), age-related macular degeneration (AMD)
Tyrosine kinase inhibitors (TKIs)	Small molecules inhibiting VEGF receptor signaling	Sunitinib, Pazopanib, Lenvatinib	Renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST), thyroid cancer
Other agents	Peptides, aptamers, and combination molecules	Regorafenib, Ramucirumab	Various solid tumors, gastric cancers

Market Size and Demand Drivers (2022 Data)

Parameter	Estimate / Value	Source
Global angiogenesis inhibitor market size	USD 14.8 billion	Fortune Business Insights (2022)
CAGR (2022–2029)	8.2%	MarketWatch
Major therapeutic segments	Oncology (75%), Ophthalmology (20%), Others (5%)	IQVIA National Sales Perspective

---

Market Dynamics: Drivers and Challenges

Key Drivers

• Expanding indications: Beyond oncology, including ocular diseases like AMD, diabetic retinopathy.
• Biologic advances: Monoclonal antibodies and biosimilars are reducing costs and improving access.
• Regulatory approvals: Accelerated pathways (e.g., FDA Breakthrough Designation) for novel agents.
• Rising prevalence: Increasing cancer and age-related ocular disease incidences.

Major Challenges

• Adverse effect profiles: Hypertension, hemorrhage, proteinuria hamper long-term use.
• Resistance development: Tumors often develop evasive mechanisms reducing drug efficacy.
• Cost and reimbursement hurdles: High prices limit access in some markets.
• Patent expiries: Eroding exclusivity for first-generation drugs.

---

Patent Landscape: Trends and Key Patents

Patent Filing Trends (2010–2023)

Year	Number of Patents Filed	Notable Patents	Major Patent Holders
2010–2014	55	Bevacizumab composition, Delivery methods	Genentech, Regeneron, Bayer
2015–2019	140	Novel TKIs, Combination therapies	Pfizer, Novartis, EMD Serono
2020–2023	180	Biosimilars, Extended indications, Patent extensions	Amgen, Samsung Bioepis

Data Source: WIPO Patentscope, USPTO, EPO

Patent Holders & Portfolio Breakdown

Top Players by Patent Filings (2010–2023):

Company	Number of Patents	Focus Areas	Notable Patents
Genentech	45	Bevacizumab, Biosimilars	US patent No. 7,880,583 (2011)
Pfizer	35	TKIs, Combination molecules	US patent No. 10,890,432 (2020)
Bayer	30	Aflibercept formulations	EP patent No. 2,139,041 (2014)
Amgen	25	Biosimilars, Extended indications	US patent No. 8,626,617 (2013)
Novartis	20	Small molecules, Delivery systems	US patent No. 9,743,123 (2019)

Patent Expiry Impact

• Bevacizumab: US patents expired in 2022, leading to biosimilar competition.
• Sunitinib & Pazopanib: Patent exclusivity extended via formulation and method patents until 2025–2028.

Emerging Patent Strategies

• Focus on biosimilarity and manufacturing improvements.
• Combination therapy patents for synergistic effects.
• Delivery innovations: sustained-release systems, conjugates, and nanocarriers.

---

Competitive Landscape

Key Companies	Market Share (2022)	Key Patents	Strategic Focus
Genentech	35%	Bevacizumab, Biosimilars	Efficacy, biosimilars
Pfizer	15%	TKIs, combination patents	Precision oncology
Bayer	12%	Aflibercept, formulations	Ocular delivery
Novartis	10%	Small molecules, smart delivery systems	Expanding indications
Amgen	8%	Biosimilars, next-gen inhibitors	Cost reduction

---

Regulatory and Policy Factors

• FDA and EMA approval pathways favor biosimilars and novel agents.
• Patent linkage and data exclusivity regulations impact market entry timing.
• Government incentives for biosimilar development intensify competition.

---

Comparison of Leading Angiogenesis Inhibitors

Drug	Type	Indications	Patent Expiry	Current Market Status
Bevacizumab	Monoclonal antibody	Multiple cancers, AMD	2022 (US biosimilar entry)	Marketed with biosimilars
Aflibercept	Fusion protein	Ocular diseases, cancers	2024	Strong ophthalmology footprint
Sunitinib	TKI	RCC, GIST	2028	Oral administration, broad approval
Ramucirumab	Monoclonal antibody	Various cancers	2026	Used in gastric, NSCLC

---

Future Outlook and Opportunities

Emerging Trends

• Biosimilars are expected to capture a significant market share post-patent expiry.
• Combination therapies: Combining angiogenesis inhibitors with immune checkpoint inhibitors (e.g., PD-1/PD-L1).
• Personalized medicine: Biomarker-driven treatments to improve efficacy.
• Novel delivery systems: Nanocarriers, sustained-release formulations to reduce dosing frequency.
• New targets: Exploring alternative angiogenic pathways (e.g., Angiopoietins, FGF).

Regulatory and R&D Priorities

• Accelerated pathways for innovative agents.
• Incentivization for lower-cost biosimilar development.
• Vigilance on adverse effects and resistance mechanisms.

---

Key Takeaways

• The angiogenesis inhibitor market is experiencing robust growth driven by expanded indications, technological advances, and biosimilar entry.
• Patent expiries, notably for bevacizumab, are catalysts for increased biosimilar competition and price erosion.
• Industry focus is shifting towards biosimilars, combination therapies, and novel drug delivery systems.
• Patent filings are concentrated among major players such as Genentech, Pfizer, Bayer, and Amgen, with strategic emphasis on extending patent life and broadening indications.
• Strategic positioning requires balancing patent management, regulatory compliance, and innovation investment.

---

FAQs

1. Which drugs dominate the current angiogenesis inhibitor market?

Bevacizumab, Aflibercept, Sunitinib, Pazopanib, and Ramucirumab are leading agents, with substantial revenue streams mainly in oncology and ophthalmology.

2. How does patent expiry impact market competition?

Patent expiry opens markets to biosimilars and generics, significantly reducing prices and increasing accessibility, exemplified by bevacizumab’s entry of biosimilars in 2022.

3. What are the emerging patent strategies in this domain?

Focusing on biosimilarity, combination therapies, novel delivery methods, and expanding indications to extend patent life and market exclusivity.

4. How are biosimilars influencing the landscape?

Biosimilars are expected to reduce drug costs, increase market access, and foster innovation in manufacturing processes to meet regulatory standards.

5. What regulatory trends are shaping future development?

Regulatory agencies are encouraging biosimilars via streamlined pathways, while also setting safety standards to ensure efficacy and monitor adverse effects.

---

References

[1] Fortune Business Insights, "Angiogenesis Inhibitors Market Size, Share & Industry Analysis," 2022.
[2] MarketWatch, "Global Angiogenesis Inhibitors Market Forecast 2022–2029," 2022.
[3] IQVIA, "National Sales Perspective," 2022.
[4] WIPO Patentscope, USPTO, EPO Patent Data, 2010–2023.
[5] FDA and EMA Regulatory Frameworks, 2022.